- Home
- STRO vs REFI Comparison
STRO vs REFI Comparison
Compare STRO & REFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STRO
- REFI
- Stock Information
- Founded
- STRO 2003
- REFI 2021
- Country
- STRO United States
- REFI United States
- Employees
- STRO N/A
- REFI N/A
- Industry
- STRO Biotechnology: Biological Products (No Diagnostic Substances)
- REFI Real Estate Investment Trusts
- Sector
- STRO Health Care
- REFI Real Estate
- Exchange
- STRO Nasdaq
- REFI Nasdaq
- Market Cap
- STRO 77.7M
- REFI 293.5M
- IPO Year
- STRO 2018
- REFI 2021
- Fundamental
- Price
- STRO $0.76
- REFI $13.95
- Analyst Decision
- STRO Hold
- REFI Strong Buy
- Analyst Count
- STRO 7
- REFI 3
- Target Price
- STRO $3.97
- REFI $20.00
- AVG Volume (30 Days)
- STRO 1.2M
- REFI 102.7K
- Earning Date
- STRO 08-12-2025
- REFI 08-06-2025
- Dividend Yield
- STRO N/A
- REFI 13.51%
- EPS Growth
- STRO N/A
- REFI N/A
- EPS
- STRO N/A
- REFI 1.88
- Revenue
- STRO $66,434,000.00
- REFI $56,790,054.00
- Revenue This Year
- STRO N/A
- REFI $15.53
- Revenue Next Year
- STRO N/A
- REFI $6.70
- P/E Ratio
- STRO N/A
- REFI $7.40
- Revenue Growth
- STRO N/A
- REFI 4.68
- 52 Week Low
- STRO $0.52
- REFI $12.76
- 52 Week High
- STRO $5.17
- REFI $16.47
- Technical
- Relative Strength Index (RSI)
- STRO 49.28
- REFI 40.80
- Support Level
- STRO $0.73
- REFI $13.85
- Resistance Level
- STRO $0.83
- REFI $14.15
- Average True Range (ATR)
- STRO 0.06
- REFI 0.25
- MACD
- STRO 0.01
- REFI -0.01
- Stochastic Oscillator
- STRO 61.90
- REFI 7.73
About STRO Sutro Biopharma Inc.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. It is mainly engaged in the development of biopharmaceutical products. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and non-Hodgkin lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. The company also pipeline contains STRO-004, STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
About REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.